Deciphera Pharmaceuticals, Inc.
DelistedCIK 1654151fmd_0BXPRQMRKEARW3AWMVWK642MA7Manufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 01, 2015 to Mar 31, 2024, 34 periods
| Line item | FY2015 | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 |
|---|---|---|---|---|---|---|---|---|---|
| Total revenues | 0 | 0 | 0 | 0 | 25 | 42 | 96 | 134 | 163 |
| Cost of revenue | – | – | – | 0 | 0 | 0 | 3 | 9 | 4 |
| Gross profit | – | – | – | 0 | 25 | 42 | 93 | 125 | 160 |
| Research and development | 12 | 20 | 40 | 83 | 158 | 199 | 257 | 188 | 234 |
| Selling, general and administrative | – | – | – | 21 | 68 | 114 | 136 | 120 | 136 |
| Total operating expenses | 18 | 26 | 51 | 104 | 226 | – | – | – | – |
| Operating income | (18) | (26) | (51) | (104) | (201) | (271) | (300) | (183) | (211) |
| Interest expense | 2 | 0 | 0 | 0 | 0 | 0 | 0 | – | – |
| Interest and investment income | – | – | – | – | – | – | 1 | 5 | 17 |
| Other non-operating income (expense) | (2) | (0) | 1 | 4 | 8 | 5 | 0 | 5 | 16 |
| Income before taxes | – | – | – | – | (192) | (266) | (300) | (178) | (195) |
| Income tax expense | – | – | 0 | 0 | 0 | 0 | 0 | 1 | 0 |
| Net income from continuing operations | – | – | – | – | (192) | (266) | (300) | (179) | (195) |
| Net income | (20) | (26) | (50) | (100) | (192) | (266) | (300) | (179) | (195) |
| Net income to common shareholders | (20) | (26) | (50) | (100) | (192) | (266) | (300) | (179) | (195) |